News of Note: Donanemab Gains FDA Approval for Early Alzheimer’s Treatment
Stephanie Collier, MD and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have no financial relationships with companies related to this material.
Stephanie Collier, MD and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have no financial relationships with companies related to this material.
Nicolás Pérez Palmer, MD
Assistant Professor of Psychiatry, Yale School of Medicine, New Haven, CT; Director of Clinical Research Services, Latino Community, Alzheimer’s Disease Research Unit; Integrated Firm Director, Psychiatry, VA Connecticut Healthcare System.
Dr. Pérez Palmer has no financial relationships with companies related to this material.
Stephanie Collier, MD. Dr. Collier has no financial relationships with companies related to this material.
Stephanie Collier, MD, MPH, and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have no financial relationships with companies related to this material.
Francisco Covino-Deaso, MSN, CNP, PMHNP-BC. Psychiatric nurse practitioner, Partial Program (PHP) at HRI Hospital, Brookline, MA.
Jennifer Holiman, MSN, CNP, PMHNP-BC. Psychiatric nurse practitioner, geriatric psychiatry outpatient program and geriatric psychiatry research program, McLean Hospital, Belmont, MA.
Mr. Covino-Deaso and Ms. Holiman have no financial relationships with companies related to this material.
Susan L. Siegfreid, MD. Dr. Siegfreid has no financial relationships with companies related to this material.
Talya Shahal, MD. Dr. Shahal, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.
James Black, MD. Dr. Black, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.
Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2024 Carlat Publishing, LLC and Affiliates, All Rights Reserved.